MBTPS1 and diabetes mellitus: The disruption of S1P pathway is the basis of systemic chronic metabolic inflammatory diseases, including diabetes and gastrointestinal cancer, which provides sufficient evidence for using S1P pathway modulators in treating pathological inflammation (152).